Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegc...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of hematology Vol. 101; no. 9; pp. 1971 - 1986
Main Authors:	Wong, Raymond S. M., Pullon, Humphrey W. H., Amine, Ismail, Bogdanovic, Andrija, Deschatelets, Pascal, Francois, Cedric G., Ignatova, Kalina, Issaragrisil, Surapol, Niparuck, Pimjai, Numbenjapon, Tontanai, Roman, Eloy, Sathar, Jameela, Xu, Raymond, Al-Adhami, Mohammed, Tan, Lisa, Tse, Eric, Grossi, Federico V.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2022 Springer Nature B.V
Subjects:	Adult Anemia Biomarkers Blood diseases Bone marrow Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Complement Inactivating Agents - adverse effects Dehydrogenases Drug dosages FDA approval Hematology Hemoglobin Hemoglobins Hemoglobinuria, Paroxysmal - drug therapy Hemolysis Hospitals Humans Medicine Medicine & Public Health Monoclonal antibodies Oncology Original Original Article Peptides, Cyclic - adverse effects Pharmaceuticals Quality of life Hemoglobin LDH Phase I/II trials Safety Paroxysmal nocturnal hemoglobinuria (PNH) Quality of life
ISSN:	0939-5555, 1432-0584, 1432-0584
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!